Key Points
- Edwards Lifesciences VP Daniel Lippis sold 619 shares on June 30 at an average price of $91.40, totaling $56,576.60. After the transaction, he still held 40,411 shares, and the sale was made under a pre-arranged Rule 10b5-1 plan.
- The stock was trading slightly lower, opening at $90.47 and down 0.8% on Wednesday, while remaining near its 52-week high of $92.88. The company also has a market cap of about $52.09 billion and a relatively low debt-to-equity ratio of 0.06.
- Recent earnings and analyst sentiment remain positive: Edwards Lifesciences beat quarterly EPS and revenue estimates, with revenue up 16.7% year over year. Analysts currently rate the stock a Moderate Buy with a consensus price target of $96.39.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 619 shares of the business's stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $91.40, for a total transaction of $56,576.60. Following the completion of the transaction, the vice president owned 40,411 shares in the company, valued at $3,693,565.40. This trade represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Trading Down 0.8%
NYSE:EW opened at $90.47 on Wednesday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $92.88. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The firm's fifty day moving average is $84.85 and its 200-day moving average is $83.36. The firm has a market cap of $52.09 billion, a P/E ratio of 48.12, a P/E/G ratio of 2.29 and a beta of 0.87.
Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences's quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.
Institutional Investors Weigh In On Edwards Lifesciences
A number of hedge funds have recently added to or reduced their stakes in EW. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $26,000. Hanson & Doremus Investment Management bought a new stake in Edwards Lifesciences during the 1st quarter valued at $25,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth $27,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth $25,000. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 79.46% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the company. Royal Bank Of Canada reissued an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. BTIG Research raised their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Tuesday. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the stock an "outperform" rating in a report on Monday, April 13th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a "hold" rating in a research note on Friday, April 24th. Finally, Wolfe Research raised Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 price target on the stock in a research note on Wednesday, April 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and a consensus target price of $96.39.
View Our Latest Stock Analysis on Edwards Lifesciences
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
